Search results
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoSanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS,...
Board trying to lower drug costs urges Marylanders to help ‘fill in’ info gaps
Maryland Matters via Yahoo News· 6 days agoThe Prescription Drug Affordability Board is seeking feedback from patients, physicians and manufactures to provide context and first-hand experience about trying to afford medications for certain ...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 4 days agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 4 days agoTotal collaboration revenues missed the Zacks Consensus Estimate of $1.32 billion. Sanofi’s...
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 3 days agoPatent expirations pose a significant threat to Regeneron's revenue, as key products may face...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 4 days agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global ...
Midday movers: Carvana and Qualcomm rise; DoorDash, Fastly, Zillow fall By Investing.com
Investing.com· 4 days agoMidday movers: Carvana and Qualcomm rise; DoorDash, Fastly, Zillow fall
What to Watch in the Day Ahead - Thursday, May 2
Reuters via Yahoo Finance· 5 days agoInvestors will expect commentary on how it plans to revive sales and updates on AI development, which is driving gains at Big Tech peers. Moderna is expected report first-quarter earnings, as ...
Regeneron records mixed results for Q1 as Eylea revenues fall
Crain's New York Business· 3 days agoThe slight dip was driven by decreases in sales of one eye disease drug, Eylea. While Schott predicted that the macular degeneration therapy would bring in $2.2 billion in sales, the medication ...